Skip to main content
. Author manuscript; available in PMC: 2022 Nov 1.
Published in final edited form as: Biomed Pharmacother. 2021 Sep 21;143:112172. doi: 10.1016/j.biopha.2021.112172

Figure 1.

Figure 1.

Treprostinil reduces kidney and liver dysfunction. (A) SCr, (B) BUN, (C) ALT, and (D) AST measured at pre-IRI (baseline) 1–72 hours post-reperfusion in control-, sham-, placebo-, and treprostinil-treated animals. Data are represented as mean ± SEM. *P<0.05, **P<0.01, ***P<0.001 vs. sham; ϕP<0.05, ϕϕP<0.01, ϕϕϕP<0.001 vs. IRI-placebo (n = 3–10/group). Two-way ANOVA, Tukey’s multiple comparisons test. (E) H&E (hematoxylin & eosin) staining of liver sections obtained from sham-operated, IRI-placebo or IRI-treprostinil rats at 6-hours post-reperfusion. Black circle and arrow indicate increased vacuolation in hepatocytes in IRI-placebo group. Data are representative of 4–5 sections per sample (n=4/group, ×400). SCr: Serum creatinine; BUN: Blood urea nitrogen; ALT: Alanine aminotransferase; AST: aspartate aminotransferase; CTRL: Control; PLB: IRI-placebo; TRE: IRI-treprostinil.